EZH2 and pancreatic neoplasm: More recent studies show that EZH2 deletion in pancreatic cancer cells increased GATA6 expression, a marker of classical PDAC subtype, indicating the presence of EZH2 promotes a more aggressive, basal-like PDAC subtype (13).